EML4 and adenocarcinoma: In the adenocarcinoma group, the main mutations were ALK (Ile1461Val), in 95.24% of patients, EML4 (Lys398Arg) in 47.62% of the patients, and EGFR (Arg521Lys) and ROS (Arg167Gln) in 42.86% of the patients (Table 3).